ClinicalTrials.gg
Not yet recruitingNCT07729397ANCILE-30Updated Nov 12, 2026

Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma

A Phase 1 interventional study of Autologous C7R.CD30-CAR-EBVSTs in Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma and Peripheral T-cell Lymphoma (PTCL), sponsored by The Methodist Hospital Research Institute. Not yet recruiting at 1 site in United States. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by The Methodist Hospital Research Institute · Phase 1, Interventional, and Treatment

How we know

Updated Nov 12, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 216 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Planned enrollment
681st of 963
21 · median 37
Started
2027
with 2 others
Phase 1
395 of 1,131
42 open now
Primary completion
2030-03
later than 194 of 215 live
Registered
1,125th of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 681st largest by planned enrollment of the 963 interventional ones that give a count, is one of 3 that started in 2027, is one of 395 in phase 1, reaches primary completion later than 194 of the 215 other live ones, and was the 1,125th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30 (C7R.CD30-CAR-EBVSTs) in patients with relapsed or refractory CD30-positive lymphomas.

Participants who meet procurement eligibility criteria will undergo collection of peripheral blood mononuclear cells for manufacture of the investigational product. Participants with a successfully manufactured product who continue to meet treatment eligibility criteria will receive lymphodepleting chemotherapy followed by infusion of autologous C7R.CD30-CAR-EBVSTs.

The primary objective is to evaluate safety. Secondary and exploratory objectives include evaluation of antitumor effect, expansion and persistence of the infused cells, and the association between immunological parameters, safety, and clinical response.

Read the detailed description

This is a Phase I study to evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes (EBVSTs) genetically modified to express a constitutively active interleukin-7 receptor (C7R) and a CD30-specific chimeric antigen receptor (CAR) (C7R.CD30-CAR-EBVSTs) in patients with relapsed or refractory CD30-positive lymphomas. The study will also evaluate the antitumor effect of C7R.CD30-CAR-EBVSTs, the expansion and persistence of the infused cells, and the association between immunological parameters, safety, and clinical response.

Autologous CD30 CAR T cells have demonstrated clinical activity in patients with relapsed or refractory CD30-positive lymphomas but have shown limited persistence. Epstein-Barr virus-specific T lymphocytes (EBVSTs) have demonstrated long-term persistence following adoptive transfer. In this study, EBVSTs are used as the cellular platform to express both a CD30 CAR and a constitutively active IL7 receptor (C7R). The investigational cell product also provides a mechanism for rapid elimination of transduced cells if clinically indicated.

Participants who meet procurement eligibility criteria will undergo collection of peripheral blood mononuclear cells for manufacture of an autologous C7R.CD30-CAR-EBVST product. Participants with a successfully manufactured product who continue to meet treatment eligibility criteria will receive lymphodepleting chemotherapy followed by intravenous infusion of C7R.CD30-CAR-EBVSTs. Participants who meet retreatment criteria, as defined in the protocol, may receive additional treatment cycles. Following treatment, participants will undergo scheduled follow-up evaluations including physical examinations, laboratory testing, and imaging studies to assess safety and disease status.

Blood samples are collected at multiple time points after infusion to evaluate persistence of the infused cells. Tumor assessments are performed using imaging and, when clinically indicated, biopsy.

Participants are followed longitudinally for up to 15 years after the most recent infusion.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Hodgkin Lymphoma
  • Peripheral T-cell Lymphoma (PTCL)
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • Anaplastic Large Cell Lymphoma, ALK-Negative

Keywords

  • CD30
  • Chimeric Antigen Receptor
  • CAR T Cells
  • Epstein-Barr Virus-Specific T Lymphocytes
  • EBVST
  • Constitutive IL7 Receptor
  • C7R
  • Gene Therapy
  • Cell Therapy
  • iC9
  • Inducible Caspase 9
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Procurement Inclusion Criteria:

Participants must meet the protocol-defined procurement eligibility criteria before collection of peripheral blood mononuclear cells for manufacture of the product, including:

  1. Diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma.
  2. CD30 positive tumor (can be pending at this time) as assayed in a CLIA certified Pathology Laboratory.
  3. Age 16 to 75 years.
  4. ≥7.0(may be transfused value).
  5. or Lansky score of > 60%
  6. explained to, understood by and signed by patient or guardian. Patient or guardian given copy of informed consent.

Procurement Exclusion Criteria:

  1. Active or HTLV infection (testing may be pending at procurement).
  2. Active bacterial, fungal, or viral infection.

    ____________________________________________________________________________

Treatment Inclusion Criteria:

Participants with a successfully manufactured product must continue to satisfy the protocol-defined treatment eligibility criteria before receiving study treatment, including:

  1. Diagnosis and clinical course falling into one of the following categories:

    • Hodgkin lymphoma
    • CD30+ aggressive B-cell lymphoma
    • ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma
    • ALK-positive anaplastic T cell lymphoma
  2. CD30 expression confirmed in a CLIA-certified laboratory. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy
  3. Age 16 to 75 years.
  4. ≤ 2 times the (except for Gilbert syndrome, where the criteria will be Bilirubin ≤ 3 times the upper limit of normal).
  5. ˂ 3 times the upper limit of normal
  6. Estimated > 50 mL/min
  7. Pulse oximetry of > 90% on room air
  8. Karnofsky or Lansky score of > 60%
  9. Sexually active patients must be willing to utilize one of the more effective methods during the study and for 6 months after study is concluded. Male partner should use a condom
  10. Informed consent explained to, understood by and signed by patient/guardian. Patient/Guardian given copy of informed consent.

Treatment Exclusion Criteria:

  1. Received an investigational cell therapy or vaccine within the past 6 weeks.
  2. Received an investigational small molecule within the past 2 weeks.
  3. Received anti-CD30 antibody-based therapy within the previous 4 weeks.
  4. History of reactions to murine protein-containing products
  5. Pregnancy or breastfeeding.
  6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion)
  7. Current use of systemic at a dose equivalent to higher than 10 mg/day of prednisone.
  8. Active significant, uncontrolled bacterial, viral or fungal infection.
  9. Symptomatic cardiac disease ( Class III or IV disease).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Autologous C7R.CD30-CAR-EBVSTs

    Participants who meet procurement eligibility criteria will undergo collection of peripheral blood mononuclear cells for manufacture of autologous C7R.CD30-CAR-EBVSTs. Participants with a successfully manufactured product who continue to meet treatment eligibility criteria will receive lymphodepleting chemotherapy followed by intravenous infusion of autologous C7R.CD30-CAR-EBVSTs. Participants who meet protocol-defined retreatment criteria may receive additional treatment cycles.

    Biological: Autologous C7R.CD30-CAR-EBVSTs

Interventions

  • BiologicalAutologous C7R.CD30-CAR-EBVSTs

    Autologous Epstein-Barr virus-specific T lymphocytes genetically modified to express a constitutively active interleukin-7 receptor (C7R), a CD30-specific chimeric antigen receptor (CAR), and an inducible caspase 9 (iC9) safety switch. The investigational product is manufactured from autologous peripheral blood mononuclear cells and administered by intravenous infusion following lymphodepleting chemotherapy.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    Dose-limiting toxicity (DLT) is defined as any of the following considered possibly, probably, or definitely related to study cellular products: (1) Grade 5 event without disease progression; (2) CRS: Grade 4, or Grade 3 not improving to ≤Grade 2 within 72 hours despite therapy; (3) ICANS: Grade 4, or Grade 3 not improving within 72 hours despite therapy; (4) Grade ≥3 IEC-HS; (5) Grade 4 neutropenia or thrombocytopenia not attributable to underlying disease or lymphodepleting chemotherapy and not improving to ≤Grade 2 within 42 days, or Grade 3 thrombocytopenia with clinically significant major bleeding; (6) Grade ≥3 vital organ toxicity (except transient hepatic or renal abnormalities improving to ≤Grade 2 within 7 days); (7) other Grade 3 toxicities not attributable to underlying disease or lymphodepleting chemotherapy and not resolving to ≤Grade 2 within 72 hours; (8) Grade ≥2 allergic reaction to T-cell infusion.

    Time frame: From initiation of lymphodepleting chemotherapy through 28 days following the initial investigational T-cell infusion.

Secondary outcomes

  1. Antitumor Effect

    Antitumor effect will be assessed by investigator evaluation of objective response (complete response and partial response) using Lugano criteria.\[

    Time frame: 4 to 6 weeks after the initial C7R.CD30-CAR-EBVST infusion.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2030, 38 months later.

Of 111 non-industry phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 83. This study's planned 38 months is below that.

Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartEst.
Jan 15, 2027
Primary completionEst.
Mar 31, 2030
CompletionEst.
Feb 28, 2044
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Autologous ICiC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Title Autologous ICiC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07729397
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
Mar 31, 2030 (estimated)
Completion
Feb 28, 2044 (estimated)
Last update
Nov 12, 2026

Study contacts

Premal Lulla, MD
Contact
lulla@bcm.edu
713-441-1450
Helen Heslop, MD
principal investigator · The Methodist Hospital Research Institute
Premal Lulla, MD
principal investigator · The Methodist Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion